# Cardiology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zora Neale Hurston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML040-SYN-TD
- Date: 1958-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Tomasz Okafor-Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Lorraine Abernathy-Osei, MD

## Reason for consultation

Breathlessness on exertion, mild ankle swelling and stage 2 blood pressure in a 67-year-old woman, with left ventricular hypertrophy on ECG and a raised NT-proBNP. Please confirm whether this is hypertensive heart disease with heart failure with preserved ejection fraction, exclude its mimics, and advise on treatment. **S**

## History

Ms. Hurston, a 67-year-old writer and substitute teacher, is seen at the request of Dr. Abernathy-Osei on the day of her echocardiogram. She has been breathless on one flight of stairs for about three months, with ankle swelling by evening and morning headaches that have gone since she started blood pressure medicines a week ago. She has no chest pain, palpitations, fainting, orthopnea or night breathlessness, no numbness of the hands, and no known kidney or thyroid disease. She has never smoked and drinks rarely. She gave a clear, precise history and asked to understand every recommendation. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 150/90, pulse 78; weight 83.4 kg |
| Neck | Jugular venous pressure not raised; no carotid bruits |
| Cardiovascular | Regular rhythm; sustained apical impulse; S4; no murmur |
| Respiratory | Clear |
| Extremities | Trace ankle edema |

BP 150/90 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 83.4 kg; BMI 30.6 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Abernathy-Osei's intake note. ECG from intake: sinus rhythm, left ventricular hypertrophy by voltage with repolarization changes, no Q waves. 24-hour ambulatory blood pressure before treatment: mean 158/96 mmHg, daytime 163/99, night 149/90, non-dipping. Home average 146/88 after one week of chlorthalidone and amlodipine. Echocardiogram this morning: ejection fraction 62%, concentric left ventricular hypertrophy (septum 13 mm, posterior wall 12 mm), grade II diastolic dysfunction with average E/e' 15, left atrial volume index 38 mL/m2, tricuspid regurgitation velocity 2.8 m/s with a normal inferior vena cava (estimated pulmonary artery systolic pressure 34 mmHg), no significant valve disease. NT-proBNP 480 pg/mL. Metabolic panel today: potassium 3.6 mmol/L, creatinine 0.94 mg/dL (eGFR 67). Urine albumin-to-creatinine ratio 22 mg/g. LDL 132 mg/dL. Sodium: 138 mmol/L; Potassium: 3.6 mmol/L; Creatinine: 0.94 mg/dL; eGFR (CKD-EPI 1953): 67 mL/min/1.73 m²; Glucose: 98 mg/dL; Magnesium: 1.9 mg/dL; LVEF by echocardiogram: 62%; Left atrial volume index: 38 mL/m² (high); Mitral E/e' ratio (average): 15 (high); KCCQ-12 overall summary: 54. All results are synthetic.

## Assessment

1. **Heart failure with preserved ejection fraction** (I50.32). Yes. Exertional breathlessness with a raised NT-proBNP, an ejection fraction of 62%, an enlarged left atrium and an E/e' of 15 meet the criteria for HFpEF; her H2FPEF score is 5 of 9 (obesity 2, two blood pressure medicines 1, age over 60 1, E/e' above 9 1; estimated pulmonary artery systolic pressure 34 mmHg, below the 35 mmHg cut point), which makes HFpEF very likely. NYHA class II. **S**
2. **Cause and mimics** (I11.0). The cause is hypertensive heart disease: high blood pressure, untreated and probably present for years, concentric hypertrophy and ECG voltage that matches the wall thickness. Transthyretin cardiac amyloidosis, including the hereditary form more common in Black Americans, should be kept in mind in HFpEF with a thick heart, but she has none of its red flags: no low voltage, no carpal tunnel or nerve symptoms, no aortic stenosis and only modest wall thickening. No technetium scan or light-chain tests are needed now; they would be if the walls thicken further or symptoms worsen despite controlled blood pressure. The valves are normal. With no angina and no Q waves or regional wall motion abnormality, stress testing is not needed. **S**
3. **Blood pressure treatment** (I11.0). Chlorthalidone with amlodipine is the right start: the 1957 guideline advises two drugs for stage 2 hypertension, and a thiazide-type diuretic with a calcium channel blocker for Black adults without kidney disease or albuminuria. The diuretic also helps her mild congestion. Target below 130/80 mmHg. If blood pressure stays above target or potassium falls on chlorthalidone, add spironolactone 12.5 mg, which also has some benefit in HFpEF. **S**
4. **Heart failure medicines and cost** (I50.32). An SGLT2 inhibitor is the first heart failure medicine to add now; it lowers heart failure hospitalization in HFpEF. Dapagliflozin or empagliflozin are equally good; use whichever she can get, through patient assistance until Extra Help begins. Spironolactone is second, as above. Sacubitril-valsartan is not needed while blood pressure can be controlled with low-cost generics. A moderate-intensity statin is reasonable for primary prevention given her blood pressure, hypertrophy and LDL. **S**
5. **Stroke risk and atrial fibrillation**. Her greatest risk is stroke: untreated stage 2 hypertension with left ventricular hypertrophy and non-dipping at night. Blood pressure control lowers that risk the most. There is no atrial fibrillation on the ECG; she does not need prolonged monitoring now, but pulse checks at visits and an ECG for any palpitations are advised, since a large left atrium raises her future risk. She should know the BE FAST signs and call 911. **S**

## Recommendations

1. Continue chlorthalidone 12.5 mg and amlodipine 5 mg daily; target below 130/80 mmHg with home readings.
2. Start dapagliflozin 10 mg daily now, with sick-day rules, through the manufacturer's patient assistance program until her drug coverage begins.
3. If blood pressure stays above target or potassium falls below 3.5 mmol/L, add spironolactone 12.5 mg daily.
4. Metabolic panel one to two weeks after each start or dose change, then every three to six months.
5. Atorvastatin 20 mg daily.
6. No stress test, technetium scan or light-chain testing now; reconsider if symptoms or wall thickness progress.
7. Daily weights with a written plan; walking most days (cardiac rehabilitation is not covered for HFpEF under Medicare's criteria).
8. Pulse check at each visit and an ECG for palpitations; teach BE FAST.
9. Repeat echocardiogram only with an unexplained change in her condition.

## Strengths and supports

- Strengths and supports: raised in Eatonville, an all-Black town she calls home; a lifelong collector of stories; describes a wide circle of friends, students and neighbors, and a sense of humor she relies on **S**

## Communication

Discussed with Dr. Abernathy-Osei, who saw her the same day. The diagnosis, the reasons for each medicine and their costs were explained to Ms. Hurston, who agreed to dapagliflozin and atorvastatin today and to spironolactone if needed. **S**

## Follow-up

Dr. Abernathy-Osei continues her care. Cardiology review in six months, or sooner if breathlessness worsens, the ejection fraction or blood pressure changes unexpectedly, or palpitations appear. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology (J Am Coll Cardiol 2023;81(18):1835-1878)
- CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
